IL17A and cervical adenocarcinoma: Indeed, the 5-year survival rate in patients with gastric adenocarcinoma (156), esophageal squamous cell carcinoma (157), chronic lymphocytic leukemia (158), ovarian cancer (159), and cervical adenocarcinoma (160) displaying increased IL-17 levels was reported to be significantly higher than survival in patients with lower IL-17 expression.